⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for cgt9486

Every month we try and update this database with for cgt9486 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid TumorsNCT02401815
Gastrointestina...
PLX9486
Pexidartinib
Sunitinib
18 Years - Cogent Biosciences, Inc.
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal TumorsNCT05208047
Advanced Gastro...
Metastatic Canc...
CGT9486 plus su...
CGT9486
Sunitinib
Sunitinib
18 Years - Cogent Biosciences, Inc.
(Apex) Bezuclastinib in Patients With Advanced Systemic MastocytosisNCT04996875
Advanced System...
SM With an Asso...
Mast Cell Leuke...
Aggressive Syst...
bezuclastinib
18 Years - Cogent Biosciences, Inc.
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic MastocytosisNCT05186753
SSM
Mastocytosis, I...
Mastocytosis, S...
Mastocytosis
Bezuclastinib T...
Bezuclastinib T...
Placebo Tablets
18 Years - Cogent Biosciences, Inc.
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: